-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Benzinga·03/18/2026 18:28:33
Listen to the news
Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $8 to $16.